Patent ID: 7749966

Claim:
A method for reducing or delaying tumor growth in an adult treated human as compared to an untreated human, the method comprising: a) providing one or more antigens, the antigen(s) characterized by the ability to stimulate the production of circulating antibodies which specifically bind to human IGF-1 when administered to a human under conditions appropriate for the stimulation of an immune response and wherein said antigen is selected from one or more of LPV-IGF1-16, LPV-IGF22-35, LPV-IGF29-42, LPV-IGF56-70, KLH-IGF28-41, KLH-IGF22-33, KLH-IGF30-38, KLH-IGF29-42, KLH-IGF22-35, KLH-IGF1-6, KLH-IGF61-70, KLH-IGF1-16, KLH-IGF56-70, KLH-IGF30-38, KLH-IGF61-70, KLH-IGF29-42, KLH-IGF56-70, Qβ-IGF28-41, Qβ-IGF22-33, Qβ-IGF30-38, Qβ-IGF29-42, Qβ-IGF22-35, Qβ-IGF1-6, Qβ-IGF61-70, Qβ-IGF1-16, Qβ-IGF56-70, Qβ-IGF30-38, Qβ-IGF61-70, Qβ-IGF29-42 and Qβ-IGF56-70; b) administering the antigen to said human to create a treated human under conditions appropriate for the stimulation of an immune response, thereby stimulating the production of circulating antibodies which specifically bind to human IGF-1; and c) correlating the administration of the antigen to said treated human with a reduction in growth of one or more tumors.